Bart Spiesschart

Company: Boehringer Ingelhiem
Job title: Principal scientist In vivo Pharmacology
Bio:
Seminars:
Conventional Cancer Treatments to Enhance Anti-Tumour Immune Activation 2:30 pm
Are radiotherapy and chemotherapy viable options to combine with OV?
This roundtable will aim to discuss how the OV-combined tumor immunotherapy can be enhanced according to the tumor location and individual patient progress.
Day: Day One
Interactive Roundtable Discussions 3:00 pm
Day: Day One